These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 24351084)

  • 21. Proteomics in prostate cancer biomarker discovery.
    Larkin SE; Zeidan B; Taylor MG; Bickers B; Al-Ruwaili J; Aukim-Hastie C; Townsend PA
    Expert Rev Proteomics; 2010 Feb; 7(1):93-102. PubMed ID: 20121479
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum proteome profiling of primary breast cancer indicates a specific biomarker profile.
    Böhm D; Keller K; Wehrwein N; Lebrecht A; Schmidt M; Kölbl H; Grus FH
    Oncol Rep; 2011 Nov; 26(5):1051-6. PubMed ID: 21837365
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proteomics approaches in the quest of kidney disease biomarkers.
    Frantzi M; Bitsika V; Charonis A; Vlahou A
    Prilozi; 2011; 32(2):33-51. PubMed ID: 22286613
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-performance proteomics as a tool in biomarker discovery.
    Meyer HE; Stühler K
    Proteomics; 2007 Sep; 7 Suppl 1():18-26. PubMed ID: 17893859
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Proteome analysis of body fluids for amyotrophic lateral sclerosis biomarker discovery.
    Krüger T; Lautenschläger J; Grosskreutz J; Rhode H
    Proteomics Clin Appl; 2013 Jan; 7(1-2):123-35. PubMed ID: 23129563
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mining the malignant ascites proteome for pancreatic cancer biomarkers.
    Kosanam H; Makawita S; Judd B; Newman A; Diamandis EP
    Proteomics; 2011 Dec; 11(23):4551-8. PubMed ID: 21932441
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biomarker discovery in lung cancer--promises and challenges of clinical proteomics.
    Bharti A; Ma PC; Salgia R
    Mass Spectrom Rev; 2007; 26(3):451-66. PubMed ID: 17407130
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inconvenient truth: cancer biomarker development by using proteomics.
    Kondo T
    Biochim Biophys Acta; 2014 May; 1844(5):861-5. PubMed ID: 23896458
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Network views for personalized medicine.
    Vlahou A
    Proteomics Clin Appl; 2013 Jun; 7(5-6):384-7. PubMed ID: 23532915
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ensembles of protein termini and specific proteolytic signatures as candidate biomarkers of disease.
    Huesgen PF; Lange PF; Overall CM
    Proteomics Clin Appl; 2014 Jun; 8(5-6):338-50. PubMed ID: 24497460
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proteomics in the diagnosis of hepatocellular carcinoma: focus on high risk hepatitis B and C patients.
    El-Aneed A; Banoub J
    Anticancer Res; 2006; 26(5A):3293-300. PubMed ID: 17094443
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proteomics-driven cancer biomarker discovery: looking to the future.
    Simpson RJ; Bernhard OK; Greening DW; Moritz RL
    Curr Opin Chem Biol; 2008 Feb; 12(1):72-7. PubMed ID: 18295612
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Breast cancer classification by proteomic technologies: current state of knowledge.
    Lam SW; Jimenez CR; Boven E
    Cancer Treat Rev; 2014 Feb; 40(1):129-38. PubMed ID: 23891266
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tissue sample preparation for biomarker discovery.
    Suehara Y; Kubota D; Saito T
    Methods Mol Biol; 2013; 1002():13-23. PubMed ID: 23625391
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Biomarker development by cancer proteomics].
    Kondo T
    Nihon Rinsho; 2012 May; 70(5):754-8. PubMed ID: 22619997
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Translation of neurological biomarkers to clinically relevant platforms.
    Hayes RL; Robinson G; Muller U; Wang KK
    Methods Mol Biol; 2009; 566():303-13. PubMed ID: 20058180
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of a novel protein isoform derived from cancer-related splicing variants using combined analysis of transcriptome and proteome.
    Hatakeyama K; Ohshima K; Fukuda Y; Ogura S; Terashima M; Yamaguchi K; Mochizuki T
    Proteomics; 2011 Jun; 11(11):2275-82. PubMed ID: 21548097
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proteomics in investigation of cancer metastasis: functional and clinical consequences and methodological challenges.
    Maryáš J; Faktor J; Dvořáková M; Struhárová I; Grell P; Bouchal P
    Proteomics; 2014 Mar; 14(4-5):426-40. PubMed ID: 24272997
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Application of proteomics in ovarian cancer: which sample should be used?
    Cadron I; Van Gorp T; Timmerman D; Amant F; Waelkens E; Vergote I
    Gynecol Oncol; 2009 Dec; 115(3):497-503. PubMed ID: 19811810
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of proteomics in prostate cancer research: biomarker discovery and validation.
    Pin E; Fredolini C; Petricoin EF
    Clin Biochem; 2013 Apr; 46(6):524-38. PubMed ID: 23266295
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.